Correction: Whole-body diffusion-weighted imaging's total diffusion volume as a significant prognostic indicator for survival in metastatic castration-resistant prostate cancer

Overview

This correction addresses the accurate authorship and grant number related to a study on whole-body diffusion-weighted imaging (WB-DWI) in metastatic castration-resistant prostate cancer (mCRPC).

Background

Whole-body diffusion-weighted imaging (WB-DWI) is recognized for its role in assessing tumor burden in metastatic castration-resistant prostate cancer (mCRPC). Accurate prognostic indicators are crucial for guiding treatment decisions.

Data Highlights

No numerical data or trial results are provided in the correction article.

Key Findings

• The author's name was corrected from Doh-Mu Koh to Dow-Mu Koh.
• The Prostate Cancer UK grant number was corrected from R746 to RIA-18-ST2-023.
• Total diffusion volume from WB-DWI is reported as a prognostic marker for survival in mCRPC.
• Previous studies have shown that WB-DWI-based metastatic tumor volume correlates with overall survival.
• Diffusion-based total lesion volume changes are reproducible and track with PSA changes after therapy.

Clinical Implications

Accurate author attribution and funding acknowledgment are essential for the integrity of scientific literature.

Conclusion

This correction ensures proper authorship and funding recognition.

Related Resources & Content

1. Koh et al., European Radiology, 2026 -- Correction: Whole-body diffusion-weighted imaging's total diffusion volume as a significant prognostic indicator for survival in metastatic castration-resistant prostate cancer
2. ASCO Publications — Quantitative parameters on whole-body diffusion weighted MRI (WB-DWMRI) and PSMA PET/CT in 177Lu-PSMA therapy for metastatic prostate cancer (mPC).
3. ASCO Publications — Quantitative parameters on whole-body diffusion weighted MRI (WB-DWMRI) and PSMA PET/CT in 177Lu-PSMA therapy for metastatic prostate cancer (mPC).
4. ASCO Publications — Radium-223: Disease response and fracture assessment by whole body diffusion-weighted MRI (WB-DWMRI) in metastatic castration resistant prostate cancer (mCRPC).
5. ASCO Publications — Detection of bone metastases through diffusion-weighted whole-body imaging with background body signal suppression (DWIBS) compared with PET/CT 18F-NaF.
6. EAU-EANM-ESTRO-ESUR-ISUP Guidelines on Prostate Cancer. Part II—2026 Update: Treatment of Relapsing and Metastatic Prostate Cancer
7. Total diffusion volume on whole-body diffusion-weighted imaging is a strong prognostic marker of disease survival in metastatic castration-resistant prostate cancer.